科研之友
微信
新浪微博
Facebook
分享链接
摘要
3,4-Dichloro-N-benzamide (AH-7921) is a cyclohexyl-methylbenzamide derivative with analgesic activity, whose abuse was associated with several fatal intoxications, included in Schedule I of UN Single Convention on Narcotic Drugs. We validated an HPLC-MS/MS method to investigate its brain disposition and metabolism after single and repeated injections; in parallel, we evaluated its central behavioral effects.
After an intraperitoneal injection of 10 mg/kg, the analgesic effect appeared after 5 min and persisted up to 4 h; brain absorption was rapid (t(max) 30 min) and large (brain-to-plasma ratio 16), with active concentration >700 ng/g. By high-resolution MS we identified several metabolites in plasma and brain, the most important being N-demethylated and N,N-didemethylated metabolites; they showed high brain permeability, although they probably do not contribute to the analgesic effect of the parent compound (brain t(max)>2 h). Starting 2 h after treatment, the two metabolites showed higher plasma and brain concentrations than the parent molecule, which persisted much longer, and could be used to evaluate drug intake in human consumers.
Tolerance was observed after seven daily doses, when the compound's analgesic effect was 14% lower than after the first dose; since brain concentrations did not decrease in parallel, the development of pharmacodynamic tolerance can be suggested. However, pharmacokinetic tolerance is also likely, as brought to light by the data after a dose challenge, given after a 48 h washout period from the 7th dose, showing a lower brain-to-plasma ratio. We also describe the rewarding effect of AH-7921 (conditioned place preference), suggesting a high risk of addiction in humans.
- 出版日期2018-5-1
